41 active trials 24 recruiting 21 Phase 3 17 disease areas 9 changes in 30 days
5 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 2 with minor changes only.
Trial terminated
Sponsor's reason: This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II.
Also in this update: Study completion date changed from estimate of Jan 2041 to Apr 9, 2025
Otsuka Pharmaceutical Co., Ltd.Phase 1/2 NCT04649073 Registry history of NCT04649073 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Feb 2026 to Sep 2027
Also in this update: Completion pushed from Mar 2026 to Oct 2027
Otsuka Pharmaceutical Co., Ltd.Phase 3 NCT05325645 Registry history of NCT05325645 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 16 locations
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT07759154 Registry history of NCT07759154 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT06894212 Registry history of NCT06894212 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 3 → 6 locations
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT07759128 Registry history of NCT07759128 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-06 | NCT07861113 A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With… | Phase 2 | Not Yet Recruiting |
| 2026-09-30 | NCT07848334 First-in-Human Safety and Tolerability Study of OPF-110 in Healthy Adults | Phase 1 | Recruiting |
| Phase 1 | 8 | |
| Phase 1/2 | 2 | |
| Phase 2 | 3 | |
| Phase 2/3 | 4 | |
| Phase 3 | 17 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07759128 | A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With… | Generalized Anxiety Disorder | Recruiting | 2026-09-22 |
| NCT05325645 | Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Acute Schizophrenia | Recruiting | 2026-09-16 |
| NCT07759154 | A Study to Test the Effects of Centanafadine in Adults With… | Attention-deficit/Hyperactivity Disorder | Recruiting | 2026-09-14 |
| NCT07767903 | A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With… | Generalized Anxiety Disorder | Recruiting | 2026-09-10 |
| NCT04782258 | A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days… | Autosomal Recessive Polycystic Kidney (ARPKD) | Recruiting | 2026-08-07 |
| NCT06971731 | A Study of JNT-517 in Participants With Phenylketonuria (PKU) | Phenylketonuria | Recruiting | 2026-07-08 |
| NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant… | Pulmonary Tuberculosis | Recruiting | 2026-05-06 |
| NCT06628128 | A Long-Term Study of JNT-517 in Participants With Phenylketonuria | Phenylketonuria (PKU) | Recruiting | 2026-05-01 |
| NCT07225712 | A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia | Schizophrenia | Recruiting | 2026-01-14 |
| NCT07087327 | A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | Attention-Deficit Hyperactivity Disorder(ADHD) | Recruiting | 2025-12-23 |
| NCT06926829 | A Long-term Trial of EB-1020 in Adult Patients With ADHD | Attention Deficit Hyperactivity Disorder (ADHD) | Recruiting | 2025-08-03 |
| NCT06894212 | A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With… | Schizophrenia | Active, Not Recruiting | 2026-10-05 |
| NCT07786454 | A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety… | Generalized Anxiety Disorder | Not Yet Recruiting | 2026-08-26 |
| NCT07770815 | Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy… | IgA Nephropathy | Not Yet Recruiting | 2026-08-18 |
| NCT05248646 | Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) | Immunoglobulin A Nephropathy | Active, Not Recruiting | 2026-07-14 |
| NCT07184645 | A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | Atopic Dermatitis (AD) | Not Yet Recruiting | 2025-09-22 |
| NCT07173478 | A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in… | Atopic Dermatitis (AD) | Not Yet Recruiting | 2025-09-15 |
| Phase 2/3 | ||||
| NCT07086313 | A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Attention-Deficit Hyperactivity Disorder(ADHD) | Recruiting | 2025-12-23 |
| NCT06589505 | Software as a Medical Device for the Treatment of Patients With PTSD | Post-Traumatic Stress Disorder, PTSD | Recruiting | 2025-11-21 |
| NCT06931080 | Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients | Attention Deficit Hyperactivity Disorder (ADHD) | Recruiting | 2025-08-03 |
| NCT05248659 | Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy | Enrolling by Invitation | 2026-05-05 |
| Phase 2 | ||||
| NCT06740526 | Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue | IgA Nephropathy | Recruiting | 2025-04-06 |
| NCT07861113 | A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With… | Primary Membranous Nephropathy | Not Yet Recruiting | 2026-10-06 |
| NCT06928142 | A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously… | Sjogren Disease | Active, Not Recruiting | 2026-03-18 |
| Phase 1/2 | ||||
| NCT06575426 | A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in… | Diabetes Mellitus, Type 1 | Recruiting | 2026-08-21 |
ADHD (5) · Schizophrenia (4) · Anxiety (3) · Lupus (SLE) (3) · Atopic Dermatitis (2) · Alzheimer's Disease (1) · Diabetes (1) · Heart Disease (1) · Heart Failure (1) · Hypertension (1)